Oncotarget

Research Papers:

N52 monodeamidated Bcl‑xL shows impaired oncogenic properties in vivo and in vitro

Florian Beaumatin, Mohamad El Dhaybi, Jean-Paul Lasserre, Bénédicte Salin, Mary Pat Moyer, Mireille Verdier, Stéphen Manon and Muriel Priault _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:17129-17143. https://doi.org/10.18632/oncotarget.7938

Metrics: PDF 767 views  |   HTML 1071 views  |   ?  


Abstract

Florian Beaumatin1,2, Mohamad El Dhaybi1,2,4, Jean-Paul Lasserre1,2, Bénédicte Salin1,2, Mary Pat Moyer3, Mireille Verdier4, Stéphen Manon1,2, Muriel Priault1,2

1CNRS, Institut de Biochimie et de Génétique Cellulaires, UMR5095, 33077 Bordeaux, France

2Université Bordeaux Ségalen, Institut de Biochimie et de Génétique Cellulaires, UMR5095, 33077 Bordeaux, France

3INCELL Corporation, San Antonio, TX 78249, USA

4EA 3842, Homéostasie Cellulaire et Pathologies, Université de Limoges, 87025 Limoges cedex, France

Correspondence to:

Muriel Priault, e-mail: muriel.priault@ibgc.cnrs.fr

Keywords: Bcl-xL, autophagy, apoptosis, cancer, post-translational modification

Received: September 29, 2015     Accepted: January 31, 2016     Published: March 06, 2016

ABSTRACT

Bcl-xL is a member of the Bcl-2 family, playing a critical role in the survival of tumor cells. Here, we show that Bcl-xL oncogenic function can be uncoupled from its anti-apoptotic activity when it is regulated by the post-translational deamidation of its Asn52.

Bcl-xL activity can be regulated by post-translational modifications: deamidation of Asn52 and 66 into Asp residues was reported to occur exclusively in response to DNA damage, and to cripple its anti-apoptotic activity. Our work reports for the first time the spontaneous occurrence of monodeamidated Asp52Bcl-xL in control conditions, in vivo and in vitro. In the normal and cancer cell lines tested, no less than 30% and up to 56% of Bcl-xL was singly deamidated on Asn52. Functional analyses revealed that singly deamidated Bcl-xL retains anti-apoptotic functions, and exhibits enhanced autophagic activity while harboring impaired clonogenic and tumorigenic properties compared to native Bcl-xL. Additionally, Asp52Bcl-xL remains phosphorylatable, and thus is still an eligible target of anti-neoplasic agents. Altogether our results complement the existing data on Bcl-xL deamidation: they challenge the common acceptance that Asn52 and Asn66 are equally eligible for deamidation, and provide a valuable improvement of our knowledge on the regulation of Bcl-xLoncogenic functions by deamidation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7938